These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21905064)

  • 21. Stratified experiments reexamined with emphasis on multicenter trials.
    Ganju J; Mehrotra DV
    Control Clin Trials; 2003 Apr; 24(2):167-81. PubMed ID: 12689738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tests of non-null hypothesis on proportions for stratified data.
    Zhao G
    Stat Med; 2008 Apr; 27(9):1429-46. PubMed ID: 17668916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re-estimating sample size in cluster randomised trials with active recruitment within clusters.
    van Schie S; Moerbeek M
    Stat Med; 2014 Aug; 33(19):3253-68. PubMed ID: 24719285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
    Baker SG; Kramer BS; Corle D
    BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
    Emberton M; Fitzpatrick JM; Rees J
    BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5alpha-reductase inhibitors/finasteride.
    Stoner E
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate.
    Timmesfeld N; Schäfer H; Müller HH
    Stat Med; 2007 May; 26(12):2449-64. PubMed ID: 17080491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Power approximation for the van Elteren test based on location-scale family of distributions.
    Zhao YD; Qu Y; Rahardja D
    J Biopharm Stat; 2006; 16(6):803-15. PubMed ID: 17146980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response adaptive designs with a variance-penalized criterion.
    Yi Y; Wang X
    Biom J; 2009 Oct; 51(5):763-73. PubMed ID: 19757432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of covariance with pre-treatment measurements in randomized trials: comparison of equal and unequal slopes.
    Funatogawa I; Funatogawa T
    Biom J; 2011 Sep; 53(5):810-21. PubMed ID: 21887795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug treatment for benign prostatic hyperplasia. Several trials have shown benefit of finasteride.
    Collins GN
    BMJ; 1997 Aug; 315(7104):371. PubMed ID: 9270474
    [No Abstract]   [Full Text] [Related]  

  • 34. Instruments and bounds for causal effects under the monotonic selection assumption.
    Taguri M; Chiba Y
    Int J Biostat; 2012 Aug; 8(1):24. PubMed ID: 22944723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
    Hausmann R; Thalmann G; Reich O; Steif CG
    Aktuelle Urol; 2004 Sep; 35(5):339-42. PubMed ID: 15383991
    [No Abstract]   [Full Text] [Related]  

  • 37. [5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked].
    MMW Fortschr Med; 2003 Jul; 145(27-28):58-9. PubMed ID: 14587193
    [No Abstract]   [Full Text] [Related]  

  • 38. A simple procedure to compute the sample size needed to compare two independent groups when the population variances are unequal.
    Singer J
    Stat Med; 2001 Apr; 20(7):1089-95. PubMed ID: 11276038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case-only analysis of treatment-covariate interactions in clinical trials.
    Vittinghoff E; Bauer DC
    Biometrics; 2006 Sep; 62(3):769-76. PubMed ID: 16984319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia].
    de la Taille A
    Prog Urol; 2008 Apr; 18 Suppl 3():S53-7. PubMed ID: 18455085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.